Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity.


Journal

Brain tumor pathology
ISSN: 1861-387X
Titre abrégé: Brain Tumor Pathol
Pays: Japan
ID NLM: 9716507

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 24 04 2023
accepted: 18 07 2023
medline: 23 10 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (pHGG) is a rare and aggressive brain tumor characterized by a specific DNA methylation profile. It was recently introduced in the 5th World Health Organization classification of central nervous system tumors of 2021. Clinical data on this tumor is scarce. This is a case series, which presents the first clinical experience with this entity. We compiled a retrospective case series on pHGG patients treated between 2015 and 2022 at our institution. Data collected include patients' clinical course, surgical procedure, histopathology, genome-wide DNA methylation analysis, imaging and adjuvant therapy. Eight pHGG were identified, ranging in age from 8 to 71 years. On MRI tumors presented with an unspecific intensity profile, T1w hypo- to isointense and T2w hyperintense, with inhomogeneous contrast enhancement, often with rim enhancement. Three patients died of the disease, with overall survival of 19, 28 and 30 months. Four patients were alive at the time of the last follow-up, 4, 5, 6 and 79 months after the initial surgery. One patient was lost to follow-up. Findings indicate that pHGG prevalence might be underestimated in the elderly population.

Identifiants

pubmed: 37561227
doi: 10.1007/s10014-023-00468-3
pii: 10.1007/s10014-023-00468-3
pmc: PMC10575802
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-214

Informations de copyright

© 2023. The Author(s).

Références

Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Acta Neuropathol Commun. 2020 Jul 9;8(1):104
pubmed: 32646492
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Acta Neuropathol. 2017 Sep;134(3):507-516
pubmed: 28401334
Acta Neuropathol. 2015 May;129(5):669-78
pubmed: 25752754
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572958
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Acta Neuropathol Commun. 2019 Jun 10;7(1):87
pubmed: 31177990
Neuro Oncol. 2020 Jan 11;22(1):116-127
pubmed: 31419298

Auteurs

Katja Bender (K)

Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Johannes Kahn (J)

Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Eilís Perez (E)

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Felix Ehret (F)

Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Siyer Roohani (S)

Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

David Capper (D)

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Simone Schmid (S)

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

David Kaul (D)

Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. david.kaul@charite.de.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany. david.kaul@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH